Orphagen Pharmaceuticals (United States)

Recent papers from Orphagen Pharmaceuticals (United States)

1. Abstract 5810: [212Pb]Pb-AG1206, A novel fibroblast activation protein-targeted radioligand therapy demonstrated excellent efficacy and safety profileCancer Research · 2026
2. Cost-effectiveness of vasopressin in the treatment of septic shock: insights from a European societal perspectiveJournal of Medical Economics · 2026
3. A Concise and Modular Approach to Generate Novel RORγ AgonistsJournal of Medicinal Chemistry · 2025
4. Pharmacological Properties of JTE-151; A Novel Orally Available RORγ Antagonist That Suppresses Th17 Cell-Related Responses in Vitro and in VivoBiological and Pharmaceutical Bulletin · 2024
5. Discovery and SAR of JTE-151: A Novel RORγ Inhibitor for Clinical DevelopmentJournal of Medicinal Chemistry · 2024
6. Discovery of Second Generation RORγ Inhibitors Composed of an Azole ScaffoldJournal of Medicinal Chemistry · 2019
7. Ternary crystal structure of human RORγ ligand-binding-domain, an inhibitor and corepressor peptide provides a new insight into corepressor interactionScientific Reports · 2018
8. Ternary complex of human RORγ ligand‐binding domain, inverse agonist and SMRT peptide shows a unique mechanism of corepressor recruitmentGenes to Cells · 2017
9. SAR Exploration Guided by LE and Fsp 3 : Discovery of a Selective and Orally Efficacious RORγ InhibitorACS Medicinal Chemistry Letters · 2015